epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-214, Phase III. Recruiting

Heart failure with reduced ejection fraction

CTS-209 added to standard care in heart failure with reduced ejection fraction. Sponsor: Contoso Pharmaceuticals (fictional), Cardiovascular.

Where EPI-214 stands on September 30th 2026

  • Randomised472of 824 needed
  • Sites open120of 120 planned
  • Median forecast finishFeb 2028Deadline Mar 2027
  • Finish11 months lateMedian forecast at the planned sites and rates, against the sponsor's deadline; the Plan tab shows the sites that would close the gap.Open the plan
  • Enrolment91% of planRandomised to date against the count the plan expected by now.Open KPIs
  • Sites60 of 113 behindSites below their own expectation. The colour pools every site against what sites of their kind should recruit, so it changes only when the shortfall is more than chance.Open Sites
  • KRIs33 of 120 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
  • QTLs1 of 4 outsideStudy-level quality limits, judged once enough patients are in.Open QTLs

One QTL needs a decision: stopped study treatment early, outside its limit.

By country

EPI-214 by country
CountrySites openRandomisedBehindWaiting too long for a first patientOver a KRI threshold
United States40 of 4010521 of 3558 of 40
United Kingdom15 of 15575 of 1416 of 15
Spain20 of 208411 of 2015 of 20
Poland20 of 201338 of 2018 of 20
Turkey10 of 10247 of 1034 of 10
India15 of 15698 of 1422 of 15